...
首页> 外文期刊>Pediatric emergency care >Evaluation of the use and safety of octreotide as antidotal therapy for sulfonylurea overdose in children
【24h】

Evaluation of the use and safety of octreotide as antidotal therapy for sulfonylurea overdose in children

机译:评价奥曲肽作为解毒剂治疗儿童过量使用磺脲类药物的安全性

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The objectives of this study were to evaluate the effect of octreotide on number of hypoglycemic episodes and blood glucose concentrations (BGCs) in a case series of young children who received octreotide for treatment of sulfonylurea-induced hypoglycemia and to identify the frequency of adverse effects associated with octreotide's use for this indication.METHODS: A retrospective review of 9 years of National Poison Data System pediatric sulfonylurea overdoses treated with octreotide was conducted.Inclusion criteria were age younger than 6 years with acute sulfonylurea overdose managed in a health care facility.Redacted poison center charts were obtained, and data on pretreatment and posttreatment number of hypoglycemic episodes and BGCs as well as medical outcomes and adverse reactions were extracted and analyzed.RESULTS: There were 121 octreotide cases.Patients experienced a median of 2.0 and 0.0 hypoglycemic episodes before and after treatment, respectively (P < 0.0001).The median lowest BGC was significantly higher after octreotide administration (P < 0.001).In 73%of children, only 1 dose of octreotide was given.Hyperglycemia was noted in 3 children who also received dextrose in whom adverse effects to therapy were coded.CONCLUSIONS: Octreotide administration decreases number of hypoglycemic events and increases BGCs.The majority of children who receive octreotide require only 1 dose.There were no adverse effects documented in these children who received octreotide as an antidote for sulfonylurea-induced hypoglycemia.
机译:目的:本研究的目的是评估在接受奥曲肽治疗磺酰脲类引起的低血糖的一系列儿童中,奥曲肽对降血糖发作次数和血糖浓度(BGC)的影响,并确定不良反应发生的频率方法:回顾性分析了使用奥曲肽治疗的9年美国国家毒物数据系统儿童小剂量磺脲类药物的纳入标准,纳入标准为年龄小于6岁且在医疗机构接受过急性磺酰脲类药物过量的治疗。结果:共有121例奥曲肽病例,患者中位血糖下降发生率分别为2.0和0.0,患者中位数为2.0和0.0。治疗前和治疗后分别(P <0.0001)。使用奥曲肽后最低BGC的中位数显着更高(P <0.001).73%的儿童仅给予1剂量的奥曲肽; 3名接受右旋糖治疗且对治疗有不良反应的儿童中发现高血糖。 :服用奥曲肽可以减少低血糖事件的发生并增加BGCs。大多数接受奥曲肽的儿童只需要1剂剂量。这些接受奥曲肽作为磺脲类药物引起的低血糖解毒剂的儿童没有任何不良反应的记录。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号